Regorafenib Tablets

Regorafenib is a novel oral multi-target kinase inhibitor that can comprehensively and continuously inhibit angiogenesis, inhibit tumor cell proliferation and tumor metastasis, and regulate the tumor immune microenvironment to exert an effective anti-immunosuppressive effect. It is mainly clinically applicable to the treatment of the following diseases:
Metastatic colorectal cancer: patients who have previously received chemotherapy based on oxaliplatin, irinotecan, and fluorouracil, and patients who have previously received or are not suitable for anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type) and anti-vascular endothelial growth factor (VEGF) therapy.
Gastrointestinal stromal tumors (GIST): patients with metastatic GIST who have previously received sunitinib malate or imatinib mesylate or locally advanced GIST that cannot be surgically removed.